WT1 and ovarian carcinoma: WT1 is over-expressed in numerous hematological malignancies like acute myeloid leukemia (AML), as well as in many solid malignancies such as ovarian cancer, thus the created WT1 TCRm CAR T-cell approach allows for the application of a single CAR to a wider array of malignancies 106-108.